An investigation into habitual potato consumption (mashed, boiled, baked) on sleep quality and chronic glycaemic control, established risk factors for cardiometabolic diseases, versus habitual consumptions of non-nutrient-dense starchy staples (white rice, pasta, and couscous).
In the last few years, researchers have undergone efforts to conduct well-controlled trials to investigate the cardiometabolic health effect of consuming potatoes as part of a healthy diet. None to our knowledge, however, have investigated the harmful dyad of poor sleep and adverse glycaemic control, 2 interrelated factors which can exacerbate cardiometabolic (CM) health outcomes. The nutrient density of potatoes, namely being the single richest source of potassium per serving, provides a plausible mechanism in which the potatoes may act to improve health markers. The primary objective of this study is to investigate whether consuming a portion of nutrient-dense potatoes in the evening meal, in place of other refined carbohydrates, can improve sleep quality, and improve nocturnal, and 24-hour, glycaemic control, both risk factors for CM diseases. Secondly, this study aims to investigate the effects of potato consumption on endothelium-dependent vasodilation, which can further interrelate to this web of interactions, and other measures of CM health. Study design: A randomised, two-parallel arm, in-clinic and remote, 12-week dietary intervention study. Study population: Healthy male and female 40-80-year-olds, who consume ≤4 fruits and vegetables per day and have sub-optimal sleep quality. The study aims to recruit a total of 80 participants, allowing for an estimated 15% dropout rate, to reach 80% power at a significance level of 0.025 (based on two outcomes). The allocation ratio is 1:1 intervention to control. Statistical analysis: Differences between groups (minimized for age, gender, BMI) will be analysed using Linear mixed models for outcomes with 3 timepoints (urinary outcomes, dietary intake data), with change being the dependent factor, subject ID as a random effect, treatment and season as fixed effects, and baseline outcome and BMI as covariates. Variables with 2 timepoints will be assessed with an ANCOVA regression model. Locations: Metabolic Research Unit, 4th floor, Franklin Wilkins Building, Waterloo campus, Kings College London, SE1 9NH. Screening assessment: Participants will be initially assessed for suitability against the inclusion-exclusion criteria via an online questionnaire. The outputs of the questionnaire will be assessed by the study team. Some exclusion criteria will be assessed at the baseline clinic visit before any baseline measures are provided. Study duration: There will be a 2-week run-in period, followed by a 12-week dietary intervention. Dietary intervention: The intervention (potato group) will consume at least 230 g of white potatoes (including fresh and frozen baked, boiled, and mashed potato products) in their evening meal, providing \~1000 mg potassium, enough to increase national median intakes up to recommended intakes. The control group will consume isoenergetic amounts of non-nutrient-dense starchy staples (white pasta, white rice, or couscous). Although participants cannot be blinded to what they're consuming, they will be blinded to whether they are in the control or the intervention group, to reduce the risk of bias. Participants will be required to source the potatoes and make these meals themselves, however, they will be provided with rotating 4-weekly recipe cards, with instructions on how to prepare meals. Participants will be required to attend several virtual one-to-ones with the study team, including an introductory call, a virtual run-in induction where they will be run through the study equipment, and 2 in-person clinic visits. Participants will be responsible for applying some study equipment from home, to reduce clinic visits and improve study retention. Compliance: Compliance will be monitored via several methods. Firstly, 24 h urinary potassium excretion, which is shown to recover 75% of potassium intake, secondly self-reported compliance will be measured through evening meal checklists. We also plan to use dietary recalls at weeks 2, 4, and 8 to reinforce dietary advice, and to make adaptations to rotating menus based on individual needs, if participants are struggling with adherence. Detailed dietary intake will be assessed through 4-day food diaries at weeks 0, 6, and 12- this data will be used for analysis. Flow-mediated dilation: A Doppler ultrasound will be utilised to capture continuous ultrasound videos to measure flow-mediated dilation. These will be analysed with automated software provided by Maastricht University. Anthropometry: Weight, height, waist and hip circumference, blood pressure, and body fat will be taken using standard procedures, in duplicates by a trained researcher at baseline and endline clinic visits. Blood samples: Fasting blood samples will be collected from a superficial antecubital vein via venepuncture before and after the dietary intervention, by a trained researcher. Participants will be asked to record and monitor the following information: Self-reported compliance with dietary intervention, weekly weight (data diaries), and habitual dietary intake (4-day diet diaries).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
71
Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
Department of Nutritional Sciences, Franklin Wilkins Building, Waterloo campus.
Lambeth, London, United Kingdom
Change in 7-day sleep efficiency
Differences in % sleep efficiency at endline vs baseline. Sleep efficiency % is described as the total time spent asleep/ total time spent in bed x 100.
Time frame: Pre- and post-intervention: 12 weeks
Change in 12-day nocturnal mean glucose
Differences in mean nocturnal glucose, measured using a Freestyle Libre 3 continuous glucose monitor.
Time frame: Pre- and post-intervention: 12 weeks
Change in mean nocturnal AUC
Difference in 12-day mean nocturnal Area Under the Curve (AUC).
Time frame: Pre- and post-intervention: 12 weeks
Difference in nocturnal TIR
Difference in 12-day nocturnal Time In Range for non-diabetic populations (TIR nd).
Time frame: Pre- and post-intervention: 12 weeks
Change in the nocturnal CV%
Difference in 12-day nocturnal coefficient of variation (CV%)
Time frame: Pre- and post-intervention: 12 weeks
Change in nocturnal MAGE
Difference in 12-day nocturnal Mean Amplitude of Glycemic Excursions (MAGE).
Time frame: Pre- and post-intervention: 12 weeks
Change in nocturnal MODD
Difference in 12-day nocturnal Mean of Daily Differences (MODD).
Time frame: Pre- and post-intervention: 12 weeks
Change in mean daytime glycaemic control
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Differences in 12-day mean daytime glucose.
Time frame: Pre- and post-intervention: 12 weeks
Difference in daytime TIR
Difference in 12-day daytime Time In Range for non-diabetic populations (TIR nd).
Time frame: Pre- and post-intervention: 12 weeks
Change in the daytime CV%
Difference in 12-day daytime coefficient of variation (CV%)
Time frame: Pre- and post-intervention: 12 weeks
Change in daytime MAGE
Difference in 12-day daytime Mean Amplitude of Glycemic Excursions (MAGE).
Time frame: Pre- and post-intervention: 12 weeks
Change in daytime MODD
Difference in 12-day daytime Mean of Daily Differences (MODD).
Time frame: Pre- and post-intervention: 12 weeks
Change in mean 24-hour glycaemic control
Differences in 12-day mean 24-hour glucose.
Time frame: Pre- and post-intervention: 12 weeks
Difference in 24-hour TIR
Difference in 12-day 24-hour Time In Range for non-diabetic populations (TIR nd).
Time frame: Pre- and post-intervention: 12 weeks
Change in the 24-hour CV%
Difference in 12-day 24-hour coefficient of variation (CV%)
Time frame: Pre- and post-intervention: 12 weeks
Change in 24-hour MAGE
Difference in 12-day 24-hour Mean Amplitude of Glycemic Excursions (MAGE).
Time frame: Pre- and post-intervention: 12 weeks
Change in 24-hour MODD
Difference in 12-day 24-hour Mean of Daily Differences (MODD).
Time frame: Pre- and post-intervention: 12 weeks
Change in heart rate variability during mental stress
A combination of time domain, frequency domain and non-linear methods (NN intervals, heart rate, rMSSD, pNN50, SDNN, TINN, SDANN, SD1/SD2, High Frequency, Low Frequency, Very Low Frequency, Ultra Low Frequency HF:LF, total power), will be compared from pre- to post-mental stress.
Time frame: Pre- and post-intervention: 12 weeks
Change in 24-hour heart rate variability
A combination of time domain, frequency domain and non-linear methods (NN intervals, heart rate, rMSSD, pNN50, SDNN, TINN, SDANN, SD1/SD2, High Frequency, Low Frequency, Very Low Frequency, Ultra Low Frequency HF:LF, total power).
Time frame: Pre- and post-intervention: 12 weeks
Change in Endothelial function
Mean differences in flow-mediated dilation (%)
Time frame: Pre- and post-intervention: 12 weeks
Nocturnal continuous blood pressure
Measured with an Aktiia Photoplethysmography watch.
Time frame: Whole 12 week period.
Daytime continuous blood pressure
Measured with an Aktiia Photoplethysmography watch.
Time frame: Whole 12 week period.
Change in blood pressure
Diastolic and systolic blood pressure, measured by oscillometry.
Time frame: Pre- and post-intervention: 12 weeks
Change in plasma lipids
Including: total lipids, HDL and LDL-cholesterol, and Triacylglycerols.
Time frame: Pre- and post-intervention: 12 weeks
Change in fasting plasma glucose
Fasting plasma glucose concentration
Time frame: Pre- and post-intervention: 12 weeks
Change in fasting insulin
Fasting insulin concentration
Time frame: Pre- and post-intervention: 12 weeks
Change in fasting HbA1C
Fasting HbA1C concentration
Time frame: Pre- and post-intervention: 12 weeks
Change in serum potassium
Serum potassium mmol/L
Time frame: Pre- and post-intervention: 12 weeks
Change in sleep duration, in minutes
Sleep duration (minutes)
Time frame: Pre- and post-intervention: 12 weeks
Change in sleep duration, in %
Sleep duration (%)
Time frame: Pre- and post-intervention: 12 weeks
Change in sleep latency
Sleep latency is defined as the time it takes to fall asleep from the time intended to fall asleep.
Time frame: Pre- and post-intervention: 12 weeks
Change in body fat %
Body fat % measured using TANITA bioelectrical impedance scales
Time frame: Pre- and post-intervention: 12 weeks
Change in waist circumference (cm)
Waist circumference (cm)
Time frame: Pre- and post-intervention: 12 weeks
Change in BMI kg/m2
BMI kg/m2, measured using a stadiometer and TANITA scales
Time frame: Pre- and post-intervention: 12 weeks
Calystegine potato biomarker
Calystegine will be analysed as an exploratory biomarker of potato consumption (a polyhydroxylated nortropane alkaloid), by Triple Quadrupole mass spectrometry (MS/MS).
Time frame: Pre- and post-intervention: 12 weeks